HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Califf Deftly Defuses Sunscreen, DSHEA Probes In Confirmation Hearing

This article was originally published in The Tan Sheet

Executive Summary

FDA commissioner nominee Robert Califf suggests adequate evidence is key to moving sunscreen TEAs through FDA’s evaluation process during his Senate confirmation hearing. He just as smoothly handled HELP Committee members’ questions about DSEHA and FDA rulemaking.

You may also be interested in...



Sharfstein Suggests Requiring Supplements Registration, Testing Standards

Oversight authorized by DSHEA “is not the regulatory system for dietary supplements sold to the American public,” says former FDA official Joshua Sharfstein.

Washington State Continues Taking Cues From California; Toxic-Free Cosmetics Act Is Back

Washington State’s Toxic-Free Cosmetics Act would ban use of any and all PFAS, matching work California started in 2020 and finished with legislation enacted last year. It also would blacklist ortho-phthalates, formaldehyde, methylene glycol and any other chemical determined by the department to release formaldehyde, among other deemed hazardous substances.

US Modernized Cosmetics Law’s ‘Weak’ Safety Substantiation Standard Leaves NGOs Wanting

Breast Cancer Prevention Partners and its Campaign for Safe Cosmetics, along with the Environmental Working Group and Women’s Voices for the Earth, see the US Modernization of Cosmetics Regulations Act of 2022 as a significant jump forward. But its “sweeping” preemption provisions could put consumers at risk, and its cosmetics safety substantiation standard is a step back from preexisting FDA regulations, the groups say.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel